Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type

Seminars in Cancer Biology

Volumn 24, Issue , 2014, Pages 33-42

  Thieblemont, Catherine ^a   Bertoni, Francesco ^b   Copie Bergman, Christiane ^c   Ferreri, Andrés J M ^d   Ponzoni, Maurilio ^d  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^c HENRI MONDOR HOSPITAL   (France)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Chronic inflammation; MALT lymphoma; Marginal zone; Microbial pathogen autoimmune disease

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; EVEROLIMUS; FLUDARABINE; IDELALISIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MITOXANTRONE; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VORINOSTAT;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CHRONIC INFLAMMATION; CLINICAL FEATURE; GASTROENTERITIS; GENE MUTATION; HASHIMOTO DISEASE; HELICOBACTER PYLORI; HUMAN; IMMUNOGENETICS; INFECTION; MARGINAL ZONE LYMPHOMA; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; STOMACH LYMPHOMA; THROMBOCYTOPENIA; THROMBOSIS; TUMOR MICROENVIRONMENT;

CHRONIC INFLAMMATION; MALT LYMPHOMA; MARGINAL ZONE; MICROBIAL PATHOGEN AUTOIMMUNE DISEASE;

B-LYMPHOCYTES; HASHIMOTO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; LYMPHOMA, B-CELL, MARGINAL ZONE; NF-KAPPA B; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; TUMOR MICROENVIRONMENT;

EID: 84892859324     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.11.005     Document Type: Review

References (156)

1. Weill J.C., Weller S., Reynaud C.A. Human marginal zone B cells. Annu Rev Immunol 2009, 27:267-285.
2. Cerutti A., Cols M., Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013, 13:118-132.
3. A clinical evaluation of the classification of International Lymphoma Study Group non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89:3909-3918.
4. Swerdow S., Campo E., Harris N., Jaffe E., Pileri S., Stein H., et al. WHO classification of tumours of haematopoietic and lymphoid tissue 2008, IARC, Lyon.
5. Wotherspoon A., Doglioni C., Diss T., Pan L., Moschini A., De Boni M., et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993, 342:575-577.
6. Coussens L., Werb Z. Inflammation and cancer. Nature 2002, 420(6917):860-867.
7. Goossens T., Klein U., Küppers R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci USA 1998, 95:2463-2468.
8. Bertoni F., Coiffier B., Salles G., Stathis A., Traverse-Glehen A., Thieblemont C., et al. MALT lymphomas: pathogenesis can drive treatment. Oncology (Williston Park) 2011, 25:1134-1142. 1147.
9. Packham G. The role of NF-kappaB in lymphoid malignancies. Br J Haematol 2008, 143:3-15.
10. Ferreri A.J., Govi S., Ponzoni M. Marginal zone lymphomas and infectious agents. Semin Cancer Biol 2013, 23:431-440.
11. Ponzoni M., Ferreri A.J., Mappa S., Pasini E., Govi S., Facchetti F., et al. Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas. Oncologist 2011, 16:1582-1588.
12. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165:2337-2344.
13. Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001, 40:275-284.
14. Du M., Diss T., Dogan A., Ye H., Aiello A., Wotherspoon A., et al. Clone-specific PCR reveals wide dissemination of gastric MALT lymphoma to the gastric mucosa. J Pathol 2000, 192:488-493.
15. Isaacson P., Chott A., Nakamura S., Müller-Hermelink H., Harris N., Swerdow S. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 214-217. IARC, Lyon. S. Swerdlow, Campo, N.L. Harris (Eds.).
16. Dreyling M., Thieblemont C., Gallamini A., Arcaini L., Campo E., Hermine O., et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013, 24:857-877.
17. Savio A., Franzin G., Wotherspoon A., Zamboni G., Negrini R., Buffoli F., et al. Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both. Blood 1996, 87:1255-1260.
18. Bertoni F., Conconi A., Capella C., Motta T., Giardini R., Ponzoni M., et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 2002, 99:2541-2544.
19. Kanellis G., Roncador G., Arribas A., Mollejo M., Montes-Moreno S., Maestre L., et al. Identification of MNDA as a new marker for nodal marginal zone lymphoma. Leukemia 2009, 23:1847-1857.
20. Falini B., Agostinelli C., Bigerna B., Pucciarini A., Pacini R., Tabarrini A., et al. IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas. Histopathology 2012, 61:930-941.
21. Greiner A., Knörr C.Q.Y., Sebald W., Schimpl A., Banchereau J., Müller-Hermelink H.K. Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation. Am J Pathol 1997, 150:1583-1593.
22. Craig V., Cogliatti S.B., Gerke A.I., Balandat C., Wündisch J.E., Müller T.A. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia 2010, 24:1186-1196.
23. García M., Bellosillo B., Sánchez Gonzáez B., García-Payarols F., Seoane A., Ferrer A.M., et al. Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome. PLoS One 2012, 7:e47396.
24. Guidoboni M., Doglioni C.L.L., Boiocchi M., Dolcetti R. Activation of infiltrating cytotoxic T lymphocytes and lymphoma cell apoptotic rates in gastric MALT lymphomas. Differences between high-grade and low-grade cases. Am J Pathol 1999, 155:823-829.
25. Sagaert X., Van Cutsem E., De Hertogh G., Geboes K., Tousseyn T. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol 2010, 7:336-346.
26. Bessède E., Copie-Bergman L.P., Levy M., Leroy K., Baia M., Riou A., et al. Is elevated gastric tissue NOX2 associated with lymphoma of mucosa-associated lymphoid tissueα. Antioxid Redox Signal 2012, 16:1205-1211.
27. Ye H., Liu H., Attygalle A., Wotherspoon A.C., Nicholson A.G., Charlotte F., et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 2003, 102:1012-1018.
28. Isaacson P., Du M. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004, 4:644-653.
29. Munari F., Lonardi S.C.M., Doglioni C., Cangi M.G., Amedei A., Facchetti F., et al. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood 2011, 117:6612-6616.
30. Ponzoni M., Ferreri A.J., Lettini G.M., Cangi A.A., Pasini M.G., Sacchi E., et al. Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods. Clin Cancer Res 2008, 14:5794-5800.
31. Suzuki A., Kobayashi M.M.K., Matsumoto T., Kawakubo M., Kumazawa S., Koide N., et al. Induction of high endothelial venule-like vessels expressing GlcNAc6ST-1-mediated L-selectin ligand carbohydrate and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) in a mouse model of "Candidatus Helicobacter heilmannii"-induced gastritis and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Helicobacter 2010, 15:538-548.
32. Kobayashi M., Mitoma J.H.H., Yu S.Y., Shimojo Y., Suzawa K., Khoo K.H., et al. Prominent expression of sialyl Lewis X-capped core 2-branched O-glycans on high endothelial venule-like vessels in gastric MALT lymphoma. J Pathol 2011, 224:67-77.
33. van Maldegem F., van Dijk R.W.T., Kluin P.M., Willemze R., Cerroni L., van Noesel C.J., et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood 2008, 112:3355-3361.
34. van Maldegem F., Wormhoudt T.A., Mulder M.M., Oud M.E., Schilder-Tol E., Musler A.R., et al. Chlamydia psittaci-negative ocular adnexal marginal zone B-cell lymphomas have biased VH4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment. Leukemia 2012, 26:1647-1653.
35. Isaacson P. The MALT lymphoma concept updated. Ann Oncol 1995, 6:319-320.
36. Jaffe E. Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis: from infection to translocation. J Natl Cancer Inst 2004, 96:571-573.
37. Bertoni F., Cazzaniga G., Bosshard G., Roggero E., Barbazza R., De Boni M., et al. Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. Br J Haematol 1997, 97:830-836.
38. Du M., Diss T., Xu C., Peng H., Isaacson P., Pan L. Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia 1996, 10:1190-1197.
39. Miklos J.A., Swerdlow S.H., Bahler D.W. Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000, 95:3878-3884.
40. Dagklis A., Ponzoni M., Govi S., Cangi M., Pasini E., Charlotte F., et al. Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation. Leukemia 2012, 26:814-821.
41. Craig V., Arnold I., Gerke C., Huynh M., Wündisch T., Neubauer A., et al. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 2010, 115:581-591.
42. Hussell T., Isaacson P., Crabtree J., Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993, 342:571-574.
43. Zucca E., Bertoni F., Roggero E., Cazzaniga G., Bosshard G., Biondi A., et al. Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach. Leukemia 1998, 12:247-249.
44. Warsame A.A., Aasheim H.C., Nustad K., Troen G., Tierens A., Wang V., et al. Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity. Blood 2011, 118:3331-3339.
45. Thorns C., Kuba J., Bernard V., Senft A., Szymczak S., Feller A., et al. Deregulation of a distinct set of microRNAs is associated with transformation of gastritis into MALT lymphoma. Virchows Arch 2012, 460:371-377.
46. Saito Y., Suzuki H., Tsugawa H., Imaeda H., Matsuzaki J., Hirata K., et al. Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS One 2012, 7(11):e47396.
47. Monsálvez V., Montes-Moreno S.A.M., Rodríguez M.E., Sanchez-Espiridion B., Lozano M., Fernández-de-Misa R., et al. MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Mod Pathol 2013, 26:171-181.
48. Craig V., Cogliatti S., Rehrauer H., Wündisch T., Müller A. Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res 2011, 71:3616-3624.
49. Cai J., Liu X.C.J., Li Y., Huang X., Li Y., Ma X., et al. MicroRNA-200 is commonly repressed in conjunctival MALT lymphoma, and targets cyclin E2. Graefes Arch Clin Exp Ophthalmol 2012, 250:523-531.
50. Yumoto N., Kurosu K., Furukawa M., Mikata A. CDR3 sequences of MALT lymphoma show homology with those of autoreactive B-cell lines. Jpn J Cancer Res 1999, 90:849-857.
51. Du M., Diss T.C., Xu C., Peng H., Isaacson P.G., Pan L. Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia 1996, 10:1190-1197.
52. Qin Y., Greiner A., Trunk M.J., Schmausser B., Ott M.M., Muller-Hermelink H.K. Somatic hypermutation in low-grade mucosa-associated lymphoid tissue-type B-cell lymphoma. Blood 1995, 86:3528-3534.
53. Bahler D.W., Miklos J.A., Swerdlow S.H. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 1997, 89:3335-3344.
54. Aarts W.M., Willemze R., Bende R.J., Meijer C.J., Pals S.T., van Noesel C.J. VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Blood 1998, 92:3857-3864.
55. Tierens A., Delabie J., Pittaluga S., Driessen A., Dewolfpeeters C. Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from different marginal zone B lymphocyte subsets. Blood 1998, 91:2381-2386.
56. Kurosu K., Yumoto N., Furukawa M., Kuriyama T., Mikata A. Low-grade pulmonary mucosa-associated lymphoid tissue lymphoma with or without intraclonal variation. Am J Respir Crit Care Med 1998, 158:1613-1619.
57. Yoshino T., Ichimura K., Mannami T., Takase S., Ohara N., Okada H., et al. Multiple organ mucosa-associated lymphoid tissue lymphomas often involve the intestine. Cancer 2001, 91:346-353.
58. Hara Y., Nakamura N., Kuze T., Hashimoto Y., Sasaki Y., Shirakawa A., et al. Immunoglobulin heavy chain gene analysis of ocular adnexal extranodal marginal zone B-cell lymphoma. Invest Ophthalmol Vis Sci 2001, 42:2450-2457.
59. Fujimori K., Shimodaira S., Akamatsu T., Furihata K., Katsuyama T., Hosaka S. Effect of Helicobacter pylori eradication on ongoing mutation of immunoglobulin genes in gastric MALT lymphoma. Br J Cancer 2005, 92:312-319.
60. Sato Y., Nakamura N., Nakamura S., Sakugawa S., Ichimura K., Tanaka T., et al. Deviated VH4 immunoglobulin gene usage is found among thyroid mucosa-associated lymphoid tissue lymphomas, similar to the usage at other sites, but is not found in thyroid diffuse large B-cell lymphomas. Mod Pathol 2006, 19:1578-1584.
61. Sakuma H., Nakamura T., Uemura N., Chiba T., Sugiyama T., Asaka M., et al. Immunoglobulin VH gene analysis in gastric MALT lymphomas. Mod Pathol 2007, 20:460-466.
62. Yoshida M., Okabe M., Eimoto T., Shimizu S., Ueda-Otsuka K., Okamoto M., et al. Immunoglobulin VH genes in thymic MALT lymphoma are biased toward a restricted repertoire and are frequently unmutated. J Pathol 2006, 208:415-422.
63. Bahler D.W., Szankasi P., Kulkarni S., Tubbs R.R., Cook J.R., Swerdlow S.H. Use of similar immunoglobulin VH gene segments by MALT lymphomas of the ocular adnexa. Mod Pathol 2009, 22:833-838.
64. Zhu D., Lossos C., Chapman-Fredricks J.R., Matthews J.M., Ikpatt O.F., Ruiz P., et al. Biased use of the IGHV4 family and evidence for antigen selection in Chlamydophila psittaci-negative ocular adnexal extranodal marginal zone lymphomas. PLoS One 2011, 6:e29114.
65. Xia H., Nakayama T., Sakuma H., Yamada S., Sato F., Takino H., et al. Analysis of API2-MALT1 fusion, trisomies, and immunoglobulin VH genes in pulmonary mucosa-associated lymphoid tissue lymphoma. Hum Pathol 2011, 42:1297-1304.
66. Thiede C., Alpen B., Morgner A., Schmidt M., Ritter M., Ehninger G., et al. Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 1998, 16:3822-3831. [published erratum appears in J Clin Oncol 1999 March;17(3):1092].
67. Kurosu K., Yumoto N., Mikata A., Taniguchi M., Kuriyama T. Monoclonality of B-cell lineage in primary pulmonary lymphoma demonstrated by immunoglobulin heavy chain gene sequence analysis of histologically non-definitive transbronchial biopsy specimens. J Pathol 1996, 178:316-322.
68. Chapman C.J., Dunn-Walters D.K., Stevenson F.K., Hussell T., Isaacson P.G., Spencer J. Sequence analysis of immunoglobulin variable region genes that encode autoantibodies expressed by lymphomas of mucosa associated lymphoid tissue. Clin Mol Pathol 1996, 49:M29-M32.
69. Du M.Q., Xu C.F., Diss T.C., Peng H.Z., Wotherspoon A.C., Isaacson P.G., et al. Intestinal dissemination of gastric mucosa-associated lymphoid tissue lymphoma. Blood 1996, 88:4445-4451.
70. Bahler D.W., Swerdlow S.H. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syndrome) begin as nonmalignant antigen-selected expansions. Blood 1998, 91:1864-1872.
71. Muramatsu H., Zou P., Suzuki H., Oda Y., Chen G.Y., Sakaguchi N., et al. Alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci 2004, 117:5405-5415.
72. Perez M., Pacchiarotti A., Frontani M., Pescarmona E., Caprini E., Lombardo G.A., et al. Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments. Br J Dermatol 2010, 162:611-618.
73. Bende R.J., Aarts W.M., Riedl R.G., de Jong D., Pals S.T., van Noesel C.J. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005, 201:1229-1241.
74. Dierlamm J., Pittaluga S., Wlodarska I., Stul M., Thomas J., Boogaerts M., et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996, 87:299-307.
75. Berger F., Traverse-Glehen A., Felman P., Callet-Bauchu E., Baseggio L., Gazzo S., et al. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity. Clin Lymphoma 2005, 5:220-224.
76. Rinaldi A., Mian M., Chigrinova E., Arcaini L., Bhagat G., Novak U., et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood 2011, 117:1595-1604.
77. Kwee I., Rancoita P.M., Rinaldi A., Ferreri A.J., Bhagat G., Gascoyne R., et al. Genomic profiles of MALT lymphomas: variability across anatomic sites. Haematologica 2011, 96:1064-1066.
78. Honma K., Tsuzuki S., Nakagawa M., Karnan S., Aizawa Y., Kim W.S., et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer 2008, 47:1-7.
79. Novak U., Rinaldi A., Kwee I., Nandula S., Rancoita P., Compagno M., et al. The NF-KB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009, 113:4918-4921.
80. Honma K., Tsuzuki S., Nakagawa M., Tagawa H., Nakamura S., Morishima Y., et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009, 114:2467-2475.
81. Rossi D., Deaglio S., Dominguez-Sola D., Rasi S., Vaisitti T., Agostinelli C., et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 2011, 118:4930-4934.
82. Rossi D., Trifonov V., Fangazio M., Bruscaggin A., Rasi S., Spina V., et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012, 209:1537-1551.
83. Chanudet E., Ye H., Ferry J., Bacon C.M., Adam P., Muller-Hermelink H.K., et al. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol 2009, 217:420-430.
84. Li Z.M., Spagnuolo L., Mensah A.A., Rinaldi A., Bhagat G., Zucca E., et al. Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis. Br J Haematol 2013, 160:719-722.
85. Dierlamm J., Wlodarska I., Michaux L., Stefanova M., Hinz K., Van den Berghe H., et al. Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol 2000, 18:1-13.
86. Streubel B., Lamprecht A., Dierlamm J., Cerroni L., Stolte M., Ott G., et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003, 101:2335-2339.
87. Dierlamm J., Baens M., Wlodarska I., Stefanova-Ouzounova M., Hernandez J., Hossfeld D., et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999, 93:3601-3609.
88. Willis T., Jadayel D., Du M., Peng H., Perry A., Abdul-Rauf M., et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999, 96:35-45.
89. Streubel B., Vinatzer U., Lamprecht A., Raderer M., Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005, 19:652-658.
90. Remstein E., Dogan A., Einerson R., Paternoster S., Fink S., Law M., et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006, 30:1546-1553.
91. Remstein E.D., James C.D., Kurtin P.J. Incidence and subtype specificity of AP12-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 2000, 156:1183-1188.
92. Murga Penas E., Hinz K., Röser K., Copie-Bergman C., Wlodarska I., Marynen P., et al. Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/MALT1 in MALT lymphomas. Leukemia 2003, 17:2225-2229.
93. Kwee I., Rancoita P., Rinaldi A., Ferreri A., Bhagat G., Gascoyne R., et al. Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica 2011, 96:1064-1066.
94. Goatly A., Bacon C., Nakamura S., Ye H., Kim I., Brown P., et al. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control. Mod Pathol 2008, 21:902-911.
95. Chanudet E., Huang Y., Zeng N., Streubel B., Chott A., Raderer M., et al. TNFAIP3 abnormalities in MALT lymphoma with autoimmunity. Br J Haematol 2011, 154:535-539.
96. Bi Y., Zeng N., Chanudet E., Huang Y., Hamoudi R., Liu H., et al. A20 inactivation in ocular adnexal MALT lymphoma. Haematologica 2012, 97:926-930.
97. Streubel B., Chott A., Huber D., Exner M., Jager U., Wagner O., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004, 351:250-259.
98. Müller-Hermelink H. Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas: marginal zone lymphomas. Hum Pathol 2003, 34:336-340.
99. Eck M., Schmausser B., Haas R., Greiner A., Czub S., Müller-Hermelink H. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 1997, 112:1482-1486.
100. Alpen B., Neubauer A., Dierlamm J., Marynen P., Thiede C., Bayerdörfer E., et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 2000, 95:4014-4015.
101. Liu H., Ruskon-Fourmestraux A., Lavergne-Slove A., Ye H., Molina T., Bouhnik Y., et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001, 357:39-40.
102. Toracchio S., Ota H., de Jong D., Wotherspoon A., Rugge M., Graham D., et al. Translocation t(11;18)(q21;q21) in gastric B-cell lymphomas. Corros Sci 2009, 100:881-887.
103. Roy N., Deveraux Q., Takahashi R., Salvesen G., Reed J. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997, 16:6914-6925.
104. Uren A., O'Rourke K., Aravind L., Pisabarro M., Seshagiri S., Koonin E., et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000, 6:961-967.
105. Zhou H., Du M., Dixit V. Consecutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005, 7:425-431.
106. Remstein E., Kurtin P., Einerson R., Paternoster S., Dewald G. Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1. Leukemia 2004, 18(January (1)):156-160.
107. Achuthan R., Bell S., Leek J., Roberts P., Horgan K., Markham A., et al. Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma. Genes Chromosomes Cancer 2000, 29:347-349.
108. Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol 2004, 4:348-359.
109. Sagaert X., de Paepe P., Libbrecht L., Vanhentenrijk V., Verhoef G., Thomas J., et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:2490-2497.
110. Haralambieva E., Adam P., Ventura R., Katzenberger T., Kalla J., Höller S., et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 2006, 20:1300-1303.
111. Sutton L., Agathangelidis A., Belessi C., Darzentas N., Davi F., Ghia P., et al. Antigen selection in B-cell lymphomas - tracing the evidence. Semin Cancer Biol 2013, 23:309-409.
112. Parsonnet J., Isaacson P.G. Bacterial infection and MALT lymphoma. N Engl J Med 2004, 350:213-215.
113. Sieniawski M., Franklin J., Nogova L., Glossmann J.P., Schober T., Nisters-Backes H., et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 2007, 25:2000-2005.
114. Verso M., Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003, 21:3665-3675.
115. Rui L., Schmitz R., Ceribelli M., Staudt L.M. Malignant pirates of the immune system. Nat Immunol 2011, 12:933-940.
116. Shaffer A.L., Young R.M., Staudt L.M. Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012, 30:565-610.
117. Staudt L.M.I.I. Therapy of DLBCL based on genomics. Hematol Oncol 2013, 31(Suppl 1):26-28.
118. Ho L., Davis R.E., Conne B., Chappuis R., Berczy M., Mhawech P., et al. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005, 105:2891-2899.
119. Zhou H., Wertz I., O'Rourke K., Ultsch M., Seshagiri S., Eby M., et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004, 427:167-171.
120. Lynch O.T., Gadina M. Ubiquitination for activation: new directions in the NF-kappaB roadmap. Mol Interv 2004, 4:144-146.
121. Che T., You Y., Wang D., Tanner M.J., Dixit V.M., Lin X. MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation. J Biol Chem 2004, 279:15870-15876.
122. Lucas P.C., McAllister-Lucas L.M., Nunez G. NF-kappaB signaling in lymphocytes: a new cast of characters. J Cell Sci 2004, 117:31-39.
123. Hu S., Du M.Q., Park S.M., Alcivar A., Qu L., Gupta S., et al. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 2006, 116:174-181.
124. Baens M., Fevery S., Sagaert X., Noels H., Hagens S., Broeckx V., et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res 2006, 66:5270-5277.
125. Noels H., van Loo G., Hagens S., Broeckx V., Beyaert R., Marynen P., et al. A novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions. J Biol Chem 2007, 282:10180-10189.
126. Vaux D.L., Silke J. RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005, 6:287-297.
127. Rosebeck S., Madden L., Jin X., Gu S., Apel I.J., Appert A., et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011, 331:468-472.
128. Liu F., Karube K., Kato H., Arita K., Yoshida N., Yamamoto K., et al. Mutation analysis of NF-kappaB signal pathway-related genes in ocular MALT lymphoma. Int J Clin Exp Pathol 2012, 5:436-441.
129. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
130. Li Z.M., Rinaldi A., Cavalli A., Mensah A.A., Ponzoni M., Gascoyne R.D., et al. MYD88 somatic mutations in MALT lymphomas. Br J Haematol 2012, 158:662-664.
131. Treon S.P., Xu L., Yang G., Zhou Y., Liu X., Cao Y., et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012, 367:826-833.
132. Vicente-Duenas C., Fontan L., Gonzalez-Herrero I., Romero-Camarero I., Segura V., Aznar M.A., et al. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad Sci USA 2012, 109:10534-10539.
133. Li Z., Wang H., Xue L., Shin D.M., Roopenian D., Xu W., et al. Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma. Blood 2009, 114:4158-4168.
134. Kondo T., Oka T., Sato H., Shinnou Y., Washio K., Takano M., et al. Accumulation of aberrant CpG hypermethylation by Helicobacter pylori infection promotes development and progression of gastric MALT lymphoma. Int J Oncol 2009, 35:547-557.
135. Sinn D., Kim Y., Lee E., Ko Y., Kim K. Methylation and API2/MALT1 fusion in colorectal extranodal marginal zone lymphoma. Mod Pathol 2009, 22:314-320.
136. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Prog 2005, 30:7-13.
137. Thieblemont C., Bastion Y., Berger F., Rieux C., Salles G., Dumontet C., et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997, 15:1624-1630.
138. Zucca E., Conconi A., Pedrinis E., Cortelazzo S., Motta T., Gospodarowicz M.K., et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003, 101:2489-2495.
139. Thieblemont C., Berger F., Dumontet C., Moullet I., Bouafia F., Felman P., et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000, 95:802-806.
140. Raderer M., Wöhrer S., Streubel B., Troch M., Turetschek K., Jäger U., et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006, 24:3136-3141.
141. Zucca E., Conconi A., Laszlo D., Lopez-Guillermo A., Bouabdallah R., Coiffier B., et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013, 31:565-572.
142. Zucca E., Conconi A., Mughal T.I., Sarris A.H., Seymour J.F., Vitolo U., et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003, 21:20-27.
143. Koch P., del Valle F., Berdel W.E., Willich N.A., Reers B., Hiddemann W., et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German multicenter study GIT NHL 01/92. J Clin Oncol 2001, 19:3874-3883.
144. Koch P., Probst A., Berdel W.E., Willich N.A., Reinartz G., Brockmann J., et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005, 23:7050-7059.
145. Du M. MALT lymphoma: many roads lead to nuclear factor-κb activation. Histopathology 2011, 58:26-38.
146. Ruskoné-Fourmestraux A., Fischbach W.A.B., Boot H., Du M.Q., Megraud F., Montalban C., et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011, 60:747-758.
147. Zucca E., Group D.M.E.G.W. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v175-v176.
148. Ferreri A., Govi S., Ponzoni M. The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. Curr Opin Oncol 2013, 25:470-479.
149. Stolte M., Bayerdorffer E., Morgner A., Alpen B., Wundisch T., Thiede C., et al. Helicobacter and gastric MALT lymphoma. Gut 2002, 50(Suppl 3):III19-III24.
150. Zullo A., Hassan C., Cristofari F., Andriani A., De Francesco V., Ierardi E., et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010, 8:105-110.
151. Ferreri A., Govi S.P.E., Mappa S., Bertoni F., Zaja F., Montalbán C., et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012, 30:2988-2994.
152. Wöhrer S., Drach J., Hejna M., Scheithauer W., Dirisamer A., Püspök A., et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol 2003, 14:1758-1761.
153. Rummel M.J., Niederle N., Maschmeyer G., Banat G.A., von Grunhagen U., Losem C., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013, 381:1202-1210.
154. Zucca E., Conconi A., Martinelli G., Tucci A., Vitolo U., Russo E., et al. Chlorambucil plus rituximab produces better event-free and progression-free survival in comparison with chlorambucil or rituximab alone in extranodal marginal zone B-cell lymphoma (MALT lymphoma): results of the IELSG-19 study. Hematol Oncol 2013, 31(S1):97-98.
155. Kiesewetter B., Troch M., Dolak W., Müllauer L., Lukas J., Zielinski C., et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica 2013, 98:353-356.
156. Samaniego F., Hagemeister F., McLaughlin P., Kwak L., Romaguera J., Fanale M., et al. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. ASCO Meeting Abstracts 2011, 29(Suppl):8030.